Amsterdam, December 2019
Annogen BV is an Amsterdam based biotech company focussed on functional genome annotation using its proprietary SuRE technology. Its sister company Gen-X BV has just signed an exclusive deal for use of SuRE for gene therapy with uniQure and consequently Annogen was incorporated with exclusive rights to commercialize the technology outside the gene therapy field. The company will apply its technology in several fields of interest including drug discovery, pharmacogenomics, cell therapy and agricultural biotechnology.
The SuRE technology enables the analysis of hundreds of millions of DNA elements for their activity as promoters or enhancers in a single experiment. The only required input is DNA and once a SuRE library is established it can analyzed and compared to other DNA sources in the controlled environment of any transfectable cell type. Thus, without the requirement of invasive biopsies, any genome of interest can be analyzed in relevant cell types and under relevant conditions, enabling the identification of regulatory DNA elements as well as the genetic variation in these elements that define traits and diseases in humans, plants and animals.
Annogen has its labs and offices at the Amsterdam Science Park.
